Sharpened focus on gene therapy led to the termination of CG01 and CGT2, with all R&D now directed to the COZY program. Cost reductions extend liquidity to Q2 2026, while financials reflect lower revenue and continued operating losses.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.